论文部分内容阅读
测定 59例甲状腺良、恶性疾病患者血清中可溶性白介素 受体 (SIL- 2 R)。结果显示 :甲状腺癌患者血清中 SIL- 2 R明显高于良性疾病组及对照组 (P <0 .0 1 )。良性腺瘤及结节性甲状腺肿与对照组间无明显差异 (P >0 .0 5)。甲状腺癌术后 5～ 1 0 d血清中 SIL- 2 R较术前增高 ,可能与术前血清中 SIL- 2 R高水平及手术干扰机体免疫有关。术后约 2 0 d基本降至正常。甲状腺癌血清中 SIL- 2 R升高与甲状腺癌的病理类型无明显关系。提示检测血清中 SIL- 2 R对判别甲状腺疾病良、恶性 ,估计疗效及预后有一定临床意义
Serum levels of soluble interleukin-2 receptor (SIL-2R) were measured in 59 patients with benign and malignant thyroid diseases. The results showed that the serum levels of SIL-2R in patients with thyroid cancer were significantly higher than those in benign diseases and controls (P <0.01). There was no significant difference between benign adenoma and nodular goiter and control group (P> 0.05). The serum levels of SIL-2R in thyroid cancer from 5 to 10 days after operation were significantly higher than those before operation, which may be related to the high level of SIL-2 R in the preoperative serum and the surgical interference with the body immunity. After about 20 days basically reduced to normal. Thyroid cancer serum SIL-2 R elevation and pathological types of thyroid cancer no significant relationship. Prompt detection of serum SIL-2 R to distinguish between benign and malignant thyroid disease, the estimated efficacy and prognosis of a certain clinical significance